• Теги
    • избранные теги
    • Компании137
      • Показать ещё
      Формат9
      Страны / Регионы19
      • Показать ещё
      Разное17
      • Показать ещё
      Международные организации1
      Люди4
      Сферы1
      Показатели5
      Издания1
Eli Lilly & Co
31 января, 23:20

Таблеткам приказано дешеветь

Дорогие лекарства признаны общественным злом и в США, и в России. Однако бороться с этой бедой будут по-разному - Трамп обещает фармкомпаниям снижение налогов, Путин намерен проверить цены с правоохранителями

31 января, 21:08

Biotech Stocks Gain on Latest Trump Drug Price Statements

President Trump continues to double down on his campaign promises, and his latest statements regarding drug prices and regulation have sent biotech stocks higher on Tuesday.

31 января, 18:57

Trump Meets Drugmakers, Demands Lower Prices

function onPlayerReadyVidible(e){'undefined'!=typeof HPTrack&&HPTrack.Vid.Vidible_track(e)}!function(e,i){if(e.vdb_Player){if('object'==typeof commercial_video){var a='',o='m.fwsitesection='+commercial_video.site_and_category;if(a+=o,commercial_video['package']){var c='&m.fwkeyvalues=sponsorship%3D'+commercial_video['package'];a+=c}e.setAttribute('vdb_params',a)}i(e.vdb_Player)}else{var t=arguments.callee;setTimeout(function(){t(e,i)},0)}}(document.getElementById('vidible_1'),onPlayerReadyVidible); U.S. President Donald Trump on Tuesday called on the pharmaceutical industry to boost U.S. production and lower prices, while also vowing to speed up approval times for new medicines and appoint a new U.S. Food and Drug Administration leader soon. Shares of five of the six drug companies at the White House meeting with Trump were up more than 1 percent on average following the president’s remarks, compared with a 0.5 percent drop in the broad S&P 500. The Nasdaq Biotech Index was up 1.1 percent, reversing earlier losses, and the S&P 500 health care index gained 0.7 percent. Attending the meeting were the CEOs of Novartis AG, Merck & Co Inc, Johnson & Johnson, Celgene Corp, Eli Lilly & Co and Amgen Inc as well as the head of the Pharmaceutical Research and Manufacturers of America lobbying group. Trump told the drugmakers that pricing had been “astronomical.” “We have to get prices down for a lot of reasons. We have no choice, for Medicare and Medicaid,” Trump said at the meeting, citing the nation’s government insurance programs for the elderly, the poor and the disabled that together are the largest U.S. purchaser of medications. Trump also said currency devaluation by other countries had increased drugmakers’ outsourcing their production and called on the companies to make more of their products in the United States. He added that foreign countries must pay fair share for drug development costs. “We’re going to end global freeloading,” Trump said. Novartis CEO Joe Jimenez, who is chairman-elect of the industry lobbying group, said last week that he wanted to talk to Trump about efforts to develop pricing models that would pay for clinical results rather than a flat price per pill, as well as plans to replace the Affordable Care Act, which is popularly known as “Obamacare.” Trump spooked investors in the pharmaceuticals and biotech sectors by saying on Jan. 11, before his inauguration, that drug companies were “getting away with murder” on what they charged the government for medicine and that he would do something about it. That prompted the pharmaceutical lobbying group to unveil a new TV marketing campaign last week to improve its image by focusing attention on strides in research. Company executives, meanwhile, have tried to tread a careful line in defending their industry while expressing optimism that the United States would continue to reward scientific advances. (Additional reporting by Eric Beech, Ben Hirschler and John Miller; Editing by Lisa Von Ahn) -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

31 января, 18:57

Trump Meets Drugmakers, Demands Lower Prices

function onPlayerReadyVidible(e){'undefined'!=typeof HPTrack&&HPTrack.Vid.Vidible_track(e)}!function(e,i){if(e.vdb_Player){if('object'==typeof commercial_video){var a='',o='m.fwsitesection='+commercial_video.site_and_category;if(a+=o,commercial_video['package']){var c='&m.fwkeyvalues=sponsorship%3D'+commercial_video['package'];a+=c}e.setAttribute('vdb_params',a)}i(e.vdb_Player)}else{var t=arguments.callee;setTimeout(function(){t(e,i)},0)}}(document.getElementById('vidible_1'),onPlayerReadyVidible); U.S. President Donald Trump on Tuesday called on the pharmaceutical industry to boost U.S. production and lower prices, while also vowing to speed up approval times for new medicines and appoint a new U.S. Food and Drug Administration leader soon. Shares of five of the six drug companies at the White House meeting with Trump were up more than 1 percent on average following the president’s remarks, compared with a 0.5 percent drop in the broad S&P 500. The Nasdaq Biotech Index was up 1.1 percent, reversing earlier losses, and the S&P 500 health care index gained 0.7 percent. Attending the meeting were the CEOs of Novartis AG, Merck & Co Inc, Johnson & Johnson, Celgene Corp, Eli Lilly & Co and Amgen Inc as well as the head of the Pharmaceutical Research and Manufacturers of America lobbying group. Trump told the drugmakers that pricing had been “astronomical.” “We have to get prices down for a lot of reasons. We have no choice, for Medicare and Medicaid,” Trump said at the meeting, citing the nation’s government insurance programs for the elderly, the poor and the disabled that together are the largest U.S. purchaser of medications. Trump also said currency devaluation by other countries had increased drugmakers’ outsourcing their production and called on the companies to make more of their products in the United States. He added that foreign countries must pay fair share for drug development costs. “We’re going to end global freeloading,” Trump said. Novartis CEO Joe Jimenez, who is chairman-elect of the industry lobbying group, said last week that he wanted to talk to Trump about efforts to develop pricing models that would pay for clinical results rather than a flat price per pill, as well as plans to replace the Affordable Care Act, which is popularly known as “Obamacare.” Trump spooked investors in the pharmaceuticals and biotech sectors by saying on Jan. 11, before his inauguration, that drug companies were “getting away with murder” on what they charged the government for medicine and that he would do something about it. That prompted the pharmaceutical lobbying group to unveil a new TV marketing campaign last week to improve its image by focusing attention on strides in research. Company executives, meanwhile, have tried to tread a careful line in defending their industry while expressing optimism that the United States would continue to reward scientific advances. (Additional reporting by Eric Beech, Ben Hirschler and John Miller; Editing by Lisa Von Ahn) -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

Выбор редакции
31 января, 16:13

Eli Lilly зафиксировала рост квартальной выручки

Американская фармацевтическая компания Eli Lilly & Co представила финансовые результаты за три месяца с окончанием в декабре. Так, чистая прибыль увеличилась с $478,4 млн или 45 центов на акцию годом ранее до $771,8 млн или 73 центов на бумагу. Выручка, тем временем, возросла на 7,2% г/г и составила $5,76 млрд. Стоит отметить, что аналитики ожидали прибыль на уровне 98 центов на одну акцию, а выручку в размере $5,55 млрд.

Выбор редакции
31 января, 15:11

Eli Lilly зафиксировала рост квартальной выручки

Американская фармацевтическая компания Eli Lilly & Co представила финансовые результаты за три месяца с окончанием в декабре. Так, чистая прибыль увеличилась с $478,4 млн или 45 центов на акцию годом ранее до $771,8 млн или 73 центов на бумагу. Выручка, тем временем, возросла на 7,2% г/г и составила $5,76 млрд. Стоит отметить, что аналитики ожидали прибыль на уровне 98 центов на одну акцию, а выручку в размере $5,55 млрд.

09 января, 17:11

Why PRIMECAP Odyssey Growth Fund (POGRX) Worth Another Look?

PRIMECAP Odyssey Growth Fund (POGRX) seeks capital appreciation

15 ноября 2016, 22:31

Investing in a Cure for Cancer: What You Need to Know

By 2030, the number of new cancer cases per year is expected to rise by 70%. How does cancer work, and why isn't there a cure yet? The post Investing in a Cure for Cancer: What You Need to Know appeared first on Visual Capitalist.

Выбор редакции
01 ноября 2016, 01:42

Biogen to invest $92 million in Puerto Rico, create 350 jobs

U.S. drugmaker Biogen Inc. is investing more than $92 million in Puerto Rico after buying assets that once belonged to Eli Lilly & Co. in the island’s southern region.

05 октября 2016, 00:26

Pence, Kaine Share Long Histories In The Fundraising Trenches

Mike Pence of Indiana has raised funds for six House races and two gubernatorial campaigns, the second of which was aborted when he was added to the GOP's presidential ticket.  (AP Photo/Charlie Neibergall, File) By: Jack Noland Though divided ideologically, Indiana's Republican Gov. Mike Pence and Democratic Sen. Tim Kaine of Virginia have traced similar paths through state and federal politics on their way to being nominated for vice president. Both have served in Congress and as governors, and now hope to assume the government's second-from-the-top job. Though they may not discuss it tonight during the campaign's only vice presidential debate, their common ground extends to fundraising, too -- at least in broad strokes. The two have relied on lawyers, Wall Street types and a handful of other well-heeled individuals to raise the copious sums they've needed for their past campaigns. A Hoosier's hunt for cash Mike Pence, tonight's surrogate for GOP White House nominee Donald Trump, was elected to the House six times, collecting $1.1 million for his first run in 2000 and almost $2.7 million for his final contest; his 12-year haul came to more than $10.3 million. After retirees, who contributed $716,789 to Pence's congressional campaigns and leadership PAC (it's not unusual for seniors to be No. 1 on any candidate's list of top donors), the securities and investment industry -- aka Wall Street -- was his most generous industry, kicking in $376,311. Lawyers and law firms were third, providing $337,914. The governor's top donors fall outside those industries, however. The conservative Club for Growth donated $90,762 to Pence's congressional campaigns through its PAC and earmarked contributions from individuals. Cummins Inc, an engine manufacturer, and Eli Lilly & Co, a pharmaceutical company, round out Pence's top three campaign contributors. Employees and PACs of these Indiana-based corporations gave $78,500 and $64,350, respectively. When Pence ran for governor of Indiana in 2012, he raised more than $14.8 million -- including $425,000 from the late Dean White, a billionaire businessman from the state; that made White Pence's top individual donor that year. Big shots of party cash came via the Republican Governors Association and the Indiana Republican Party, which gave $1.1 million and $811,504, respectively. Pence also picked up $220,000 and $200,000 contributions from conservative bigwigs like Texas homebuilder Bob Perry, who passed away in 2013, and billionaire industrialist David Koch. After joining the presidential ticket in July, Pence dropped his 2016 re-election bid, having already raised more than $16.1 million. The RGA, Pence's top funder in 2012, had contributed more than $3 million, and the governor also collected $300,634 from Anthony Moravec, the CEO of Columbus-based Applied Laboratories, Inc., and another $100,000 from David Koch. White, who died in September, also contributed $350,000 to Pence's 2016 reelection effort. Trump and the governor will be unable to cultivate much hedge fund or private equity industry cash in 2016 -- at least not directly. That's because the SEC's so-called pay-to-play rule, implemented in 2010, caps the amount "SEC registered hedge fund advisers" can contribute to sitting state or local officials at $250-$350. Designed to prevent bankers and politicians from exchanging campaign contributions for the lucrative right to manage state pension funds, the rule triggered a Goldman Sachs memo banning certain categories of employees from donating to campaigns that feature a sitting state or local official. The Trump-Pence ticket is specifically listed as an example of a campaign to which employees may not contribute. Are there workarounds? Sure, including gifts to the Republican party. Pence's personal finances are less robust than his campaign coffers. His net worth in 2012 was estimated at $211,511. New documents are no more revealing: Pence's 2016 financial disclosure form reports his $173,860 gubernatorial salary and lists student loans for his children's education as his only liabilities. Multiple Kaine candidacies required millions Tim Kaine has moved relatively quickly between jobs over his political career. He was mayor of Richmond, lieutenant governor and then governor of Virginia, chairman of the Democratic National Committee and finally U.S. senator, the position he still holds, in a span of 18 years. Democrat Tim Kaine of Virginia has had to raise money to run for mayor of Richmond, lieutenant governor and governor, and senator -- and a huge part of his job at the DNC involved harvesting cash for his party. (AP Photo/Chuck Burton, File) For his 2001 lieutenant governor's race, Kaine raised almost $2.4 million, according to National Institute on Money in State Politics records. At the top, his haul included $50,000 from the DNC and $40,000 from Virginia real estate magnate Gerald Halpin. When Kaine ran for governor in 2005, he ratcheted up his fundraising efforts, collecting more than $18 million over the course of the cycle. Like Pence, he benefited from hefty cash infusions from the party, including $1.5 million from the DNC and $685,242 from the Virginia Democratic Party. Kaine also earned $662,964 in unitemized (small) donations and did well with unions, too: the SEIU, Laborers Local 980, Virginia AFL-CIO and IBEW each kicked in six-figure contributions. Among individuals backing Kaine, billionaire Sheila Johnson, who cofounded Black Entertainment Television and now heads Salamander Hotels and Resorts, made six donations worth a total $392,490 that year. Cisco Systems cofounder Sandy Lerner and real estate developer B. Mark Fried each gave Kaine more than $175,000. After leaving Richmond and serving as the chairman of the DNC (where corralling cash was a major part of the job), Kaine ran in 2012 for the Senate seat fellow Democrat Jim Webb announced he would be vacating. Kaine ultimately outraised Republican former Sen. George Allen in the general election, pulling in $18 million to his opponent's $14.5 million. Over the course of his Senate career, Kaine has raised the most cash from lawyers and affiliated PACs, taking in more than $2.7 million. Like Pence, he has benefited from heavy support from retirees, who have given the senator more than $2.1 million. Employees and PACs in the securities and investment industry come in at No. 3 on Kaine's list, having contributed almost $1.1 million. Kaine's top contributor has been JStreetPAC, a liberal pro-Israel group, leads the way. The PAC and individuals earmarking gifts to Kaine through it have provided him with $178,283 during his Senate run and since. Running just behind is the League of Conservation Voters, which also passed along gifts marked for Kaine; it provided $177,129. Employees of Covington & Burling, a D.C.-based law firm, gave more than $100,000. Kaine's net worth, estimated to be roughly $1.45 million in 2014, was far below the Senate average of $10.2 million. The senator's single outstanding liability then was a 15-year mortgage, and his financial reports list his board memberships at the Myotonic Dystrophy Foundation and the US-Spain Council. Kaine's income tax returns, released in August, show that he and his wife, former Virginia Secretary of Education Anne Holton, together earned $313,441 last year. While Kaine was lieutenant governor and then governor, he also accepted more than $160,000 worth of gifts, including vacation lodging, clothes and airfare, Politico reported. While the gifts were properly disclosed and legally permissible under Virginia law, the state's in-kind donation laws recently came into the spotlight when the U.S. Supreme Court in June unanimously overturned former Virginia Gov. Bob McDonnell's (R) ethics conviction, which stemmed from undisclosed gifts and charges of quid-pro-quo corruption. Pence and Kaine face off at Longwood University in Farmville, Va., tonight at 9 p.m. ET. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

Выбор редакции
26 июля 2016, 15:35

Квартальные продажи Eli Lilly превысили прогнозы аналитиков

Американская фармацевтическая компания Eli Lilly & Co представила финансовые результаты за три месяца с окончанием в июне. Так, прибыль составила $747,7 млн или 71 цент на акцию по сравнению с $600,8 млн или 56 центами на бумагу годом ранее. Заметим, что прибыль за исключением некоторых статей сократилась с 90 центов на акцию годом ранее до 86 центов на бумагу, что совпало с ожиданиями рынка. Продажи, тем временем, увеличились на 8,6% г/г и составили $5,4 млрд, тогда как аналитики прогнозировали $5,15 млрд.

Выбор редакции
26 июля 2016, 14:51

Квартальные продажи Eli Lilly превысили прогнозы аналитиков

Американская фармацевтическая компания Eli Lilly & Co представила финансовые результаты за три месяца с окончанием в июне. Так, прибыль составила $747,7 млн или 71 цент на акцию по сравнению с $600,8 млн или 56 центами на бумагу годом ранее. Заметим, что прибыль за исключением некоторых статей сократилась с 90 центов на акцию годом ранее до 86 центов на бумагу, что совпало с ожиданиями рынка. Продажи, тем временем, увеличились на 8,6% г/г и составили $5,4 млрд, тогда как аналитики прогнозировали $5,15 млрд.

26 июля 2016, 14:00

Сегодня в США ожидается шквал информации

Во вторник, 26 июля, в Соединенных Штатах Америки ожидается публикация ряда важных макроэкономических показателей. В 17:00 МСК будет представлена информация по продажам нового жилья за июнь. Согласно прогнозам, показатель составил 0,560 млн после 0,551 месяцем ранее. В это же время будет опубликован индекс потребительского доверия за июль. Отметим, что в прошлом месяце он составил 98 пунктов. Среди второстепенных данных можно отметить недельные индексы сопоставимых продаж в розничных сетях, включая данные Красной книги. О квартальных результатах сегодня отчитаются компанииVerizon Communications, Caterpillar,EI du Pont de Nemours & Co, Freeport-McMoRan, Eli Lilly & Co, McDonald's, 3M, United Technologies, KeyCorp, Valero Energy, Centene (до открытия), а также Apple, Linear Technology, Juniper Networks (после закрытия).

25 июля 2016, 15:24

Сегодня в США ожидается шквал информации

Во вторник, 26 июля, в Соединенных Штатах Америки ожидается публикация ряда важных макроэкономических показателей. В 17:00 МСК будет представлена информация по продажам нового жилья за июнь. Согласно прогнозам, показатель составил 0,560 млн после 0,551 месяцем ранее. В это же время будет опубликован индекс потребительского доверия за июль. Отметим, что в прошлом месяце он составил 98 пунктов. Среди второстепенных данных можно отметить недельные индексы сопоставимых продаж в розничных сетях, включая данные Красной книги. О квартальных результатах сегодня отчитаются компании EI du Pont de Nemours & Co, Freeport-McMoRan, Eli Lilly & Co, McDonald's, 3M, United Technologies, KeyCorp, Valero Energy, Centene (до открытия), а также Apple, Linear Technology, Juniper Networks (после закрытия). К 13:45 МСК фьючерсы на индекс S&P 500 торгуются с понижениемна 0,080%.

Выбор редакции
26 апреля 2016, 16:23

Квартальная выручка Eli Lilly превысила прогнозы аналитиков

Американская фармацевтическая компания Eli Lilly & Co представила финансовые результаты за первый квартал. Согласно отчету компании, чистая прибыль составила $440 млн или 41 цент на акцию по сравнению с прибылью в $530 млн или 50 центов на бумагу годом ранее. Между тем, прибыль за исключением некоторых статей оказалась на уровне 83 центов на акцию, тогда как аналитики прогнозировали 85 центов. Выручка в рассматриваемом периоде возросла на 5% г/г до $4,87 млрд, хотя аналитики ожидали $4,82 млрд.

Выбор редакции
26 апреля 2016, 14:50

Квартальная выручка Eli Lilly превысила прогнозы аналитиков

Американская фармацевтическая компания Eli Lilly & Co представила финансовые результаты за первый квартал. Согласно отчету компании, чистая прибыль составила $440 млн или 41 цент на акцию по сравнению с прибылью в $530 млн или 50 центов на бумагу годом ранее. Между тем, прибыль за исключением некоторых статей оказалась на уровне 83 центов на акцию, тогда как аналитики прогнозировали 85 центов. Выручка в рассматриваемом периоде возросла на 5% г/г до $4,87 млрд, хотя аналитики ожидали $4,82 млрд.

Выбор редакции
05 января 2016, 18:33

Eli Lilly пересмотрела прогнозы на 2016 год

Американская фармацевтическая компания Eli Lilly & Co. пересмотрела прогнозы по прибыли и выручке на 2016 год. Так, по обновленным оценкам компании, выручка составит $20,2-20,7 млрд, а скорректированная прибыль на одну акцию может достичь $3,45-3,55. Заметим, что аналитики в среднем прогнозируют прибыль на акцию на уровне $3,65 при выручке в $21,6 млрд.

22 октября 2015, 14:00

Сегодня в США ожидается: масса интересного

В четверг, 22 октября, в Соединенных Штатах Америки ожидается публикация ряда важных макроэкономических показателей и отчетностей. В 15:30 МСК ожидается актуальная информация по количеству первичных обращений за пособиями по безработице за неделю. В 17:00 МСК будут опубликованы данные по продажам домов на вторичном рынке за сентябрь. Согласно прогнозам, показатель составил 5,38 млн после 5,31 млн месяцем ранее. Среди второстепенных данных можно отметить недельное изменение запасов природного газа, а также индекс деловой активности в промышленности ФРБ Канзаса. О квартальных результатах сегодня отчитается компании Dow Chemical, Freeport-McMoRan, Eli Lilly & Co, PulteGroup, Danaher, Nasdaq, 3M, Caterpillar, United Continental, McDonald's (до открытия), а также Microsoft, Amazon.com, Alphabet, AT&T (после закрытия). К 13:50 МСК фьючерсы на индекс S&P 500 торгуются с повышением на 0,294%.

22 октября 2015, 09:37

Сегодня в США ожидается: масса интересного

В четверг, 22 октября, в Соединенных Штатах Америки ожидается публикация ряда важных макроэкономических показателей и отчетностей. В 15:30 МСК ожидается актуальная информация по количеству первичных обращений за пособиями по безработице за неделю. В 17:00 МСК будут опубликованы данные по продажам домов на вторичном рынке за сентябрь. Согласно прогнозам, показатель составил 5,38 млн после 5,31 млн месяцем ранее. Среди второстепенных данных можно отметить недельное изменение запасов природного газа, а также индекс деловой активности в промышленности ФРБ Канзаса. О квартальных результатах сегодня отчитается компании Dow Chemical, Freeport-McMoRan, Eli Lilly & Co, PulteGroup, Danaher, Nasdaq, 3M, Caterpillar, United Continental, McDonald's (до открытия), а также Microsoft, Amazon.com, Alphabet, AT&T (после закрытия). К 13:50 МСК фьючерсы на индекс S&P 500 торгуются с повышением на 0,294%.